Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in Russia. When patients develop resistance or intolerance to imatinib, second generation tyrosine kinase inhibitors (Tkis) are used. in Russia, nilotinib, dasatinib and bosutini...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Livro |
| Publicado em: |
IRBIS LLC,
2018-08-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Área/Cota: |
A1234.567 |
|---|---|
| Cód. Barras: 1 | Disponível |